keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine tumor metastasic treatment

keyword
https://www.readbyqxmd.com/read/28334992/utility-of-chromogranin-b-compared-with-chromogranin-a-as-a-biomarker-in-japanese-patients-with-pancreatic-neuroendocrine-tumors
#1
Masami Miki, Tetsuhide Ito, Masayuki Hijioka, Lingaku Lee, Kohei Yasunaga, Keijiro Ueda, Takashi Fujiyama, Yuichi Tachibana, Ken Kawabe, Robert T Jensen, Yoshihiro Ogawa
Objective: Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker. Methods: Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features...
March 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28331340/pancreatic-neuroendocrine-neoplasms-at-magnetic-resonance-imaging-comparison-between-grade-3-and-grade-1-2-tumors
#2
Chuangen Guo, Xiao Chen, Wenbo Xiao, Qidong Wang, Ke Sun, Zhongqiu Wang
BACKGROUND: The grading of pancreatic neuroendocrine neoplasms (PanNENs) is associated with the choice of treatment strategy. The aim of this study is to identify the magnetic resonance imaging (MRI) features in differentiating pancreatic neuroendocrine tumors (PanNETs) grade 1/2 (G1/G2) and pancreatic neuroendocrine carcinoma grade 3 (PanNEC G3). PATIENTS AND METHODS: A total of 59 patients with histologically proven PanNENs and who underwent pretreatment MRI were retrospectively analyzed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28329738/transarterial-chemo-embolization-for-liver-metastases-in-patients-with-neuroendocrine-tumors
#3
Hiroyuki Okuyama, Masafumi Ikeda, Hideaki Takahashi, Izumi Ohno, Yusuke Hashimoto, Shuichi Mitsunaga, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Tatsushi Kobayashi, Yasuaki Arai, Takuji Okusaka
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of transarterial (chemo)embolization [TA(C)E] for the control of liver metastasis in patients with neuroendocrine tumors (NETs). METHODS: In this retrospective study, we enrolled 43 patients with metastatic NETs who had been treated with TA(C)E between December 1999 and June 2013 at the National Cancer Center Hospital, Tokyo or the National Cancer Center Hospital East, Kashiwa. We assessed tumor response, time to treatment failure (TTF), overall survival (OS), and frequency of adverse events in these patients, and attempted to identify predictors of TTF...
March 23, 2017: Oncology
https://www.readbyqxmd.com/read/28314296/perfusion-ct-changes-in-liver-metastases-from-pancreatic-neuroendocrine-tumors-during-everolimus-treatment
#4
Mirko D'Onofrio, Sara Cingarlini, Silvia Ortolani, Stefano Crosara, Riccardo DE Robertis, Paola Vallerio, Elisabetta Grego, Valentina Ciaravino, Andrea Ruzzenente, Luca Landoni, Aldo Scarpa, Claudio Bassi, Giampaolo Tortora
AIM: To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. PATIENTS AND METHODS: All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303430/management-of-neuroendocrine-tumor-liver-metastases-long-term-outcomes-and-prognostic-factors-from-a-large-prospective-database
#5
Mark Fairweather, Richard Swanson, Jiping Wang, Lauren K Brais, Trevor Dutton, Matthew H Kulke, Thomas E Clancy
BACKGROUND: Liver-directed therapies have been used to treat neuroendocrine liver metastases (NELM) for both symptomatic improvement and tumor growth control. We reviewed our experience with NELM to investigate the outcomes of available treatment modalities and to identify prognostic factors for survival. METHODS: We identified all patients with NELM, who were managed at our institution, from a prospectively collected institutional database. Overall survival (OS) was determined for each treatment modality...
March 16, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28302003/liver-transplant-for-nonhepatocellular-carcinoma-malignancy
#6
Nihan Haberal Reyhan
Liver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present...
March 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28254159/surveillance-strategy-for-small-asymptomatic-non-functional-pancreatic-neuroendocrine-tumors-a-systematic-review-and-meta-analysis
#7
REVIEW
Ville Sallinen, Tessa Y S Le Large, Shamil Galeev, Zahar Kovalenko, Elke Tieftrunk, Raphael Araujo, Güralp O Ceyhan, Sebastien Gaujoux
BACKGROUND: Non-functional pancreatic neuroendocrine tumors (NF-PNET) are rare neoplasms being increasingly diagnosed. Surgical treatment or expectant management are both suggested for small NF-PNETs. The aim of this study was to evaluate the outcome of surveillance strategy for small NF-PNETs. METHODS: A systematic search was performed up to March 2016 in MEDLINE, EMBASE and the Cochrane Library according to the PRISMA guidelines. Data was pooled using the random-effects model...
February 18, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28250297/multimodal-treatment-of-vasoactive-intestinal-polypeptide-producing-pancreatic-neuroendocrine-tumors-with-liver-metastases
#8
Mari Iwasaki, Kouhei Tsuchida, Hidehito Jinnai, Toshinori Komatsubara, Takahiro Arisaka, Misako Tsunemi, Masakazu Nakano, Makoto Iijima, Hideyuki Hiraishi
A 53-year-old man presented with diarrhoea and hypokalaemia and was diagnosed with a neuroendocrine tumour of unknown origin with multiple liver metastases. Somatostatin analogues led to a reduction in the size of the tumours and improvement of his symptoms. However, after several years, the tumours grew in size, and the patient's clinical symptoms recurred. The patient underwent transcatheter arterial embolization (TAE) of the hepatic artery to treat the liver metastases. Immediately after embolization, the symptoms disappeared...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28228136/circulating-tumor-cells-capture-disease-evolution-in-advanced-prostate-cancer
#9
Justin Lack, Marc Gillard, Maggie Cam, Gladell P Paner, David J VanderWeele
BACKGROUND: Genetic analysis of advanced cancer is limited by availability of representative tissue. Biopsies of prostate cancer metastasized to bone are invasive with low quantity of tumor tissue. The prostate cancer genome is dynamic, however, with temporal heterogeneity requiring repeated evaluation as the disease evolves. Circulating tumor cells (CTCs) offer an alternative, "liquid biopsy", though single CTC sequencing efforts are laborious with high failure rates. METHODS: We performed exome sequencing of matched treatment-naïve tumor tissue, castrate resistant tumor tissue, and pooled CTC samples, and compared mutations identified in each...
February 23, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28210088/clinicopathological-treatment-and-prognosis-study-of-43-gastric-neuroendocrine-carcinomas
#10
De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
AIM: To provide more information and therapeutic methods about gastric neuroendocrine carcinomas (G-NECs) which occur rarely but are highly malignant and clinically challenging. METHODS: We retrospectively analyzed the clinicopathological characteristics, treatments, and prognosis of 43 G-NEC patients at our hospital between January 2007 and December 2014. The diagnosis was based on the 2010 World Health Organization criteria. RESULTS: Forty-three G-NECs containing 39 small cell carcinomas and 4 large cell NECs with Ki67 > 60% were included in this study, accounting for only 0...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28205418/pediatric-neuroendocrine-carcinoid-tumors-management-pathology-and-imaging-findings-in-a-pediatric-referral-center
#11
Andrew J Degnan, Shannon Tocchio, Waleed Kurtom, Sameh S Tadros
BACKGROUND: While neuroendocrine (carcinoid) tumors are increasingly recognized in the adult population, they are often not suspected in children. PROCEDURE: Retrospective review of all well-differentiated neuroendocrine (carcinoid) tumors was performed based on pathology reports from a quaternary pediatric medical center between January 2003 and June 2016. Clinical presentations, treatment approaches, imaging findings, and outcomes were reviewed and analyzed. RESULTS: A total of 45 cases of pathology-proven carcinoid tumor were reported with an average age of 14...
February 16, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28204963/peritoneal-metastases-from-gastroenteropancreatic-neuroendocrine-tumors-incidence-risk-factors-and-prognosis
#12
Ariana Madani, Irene Thomassen, Yvette R B M van Gestel, Jarmila D W van der Bilt, Harm R Haak, Ignace H J T de Hingh, Valery E P P Lemmens
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms and data on peritoneal metastases (PM) from these tumors are scarce. OBJECTIVE: The aim of this study was to present population-based data on the incidence, risk factors, and survival of synchronous PM in GEP-NETs. METHODS: Data from all patients diagnosed with a GEP-NET during 2007-2013 were collected from the Netherlands Cancer Registry. Age-standardized incidence rates were calculated and risk factors for developing PM were determined using multivariable logistic regression analysis...
February 15, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#13
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28199067/human-epididymis-protein-4-immunostaining-of-malignant-ascites-differentiates-cancer-of-m%C3%A3-llerian-origin-from-gastrointestinal-cancer
#14
Anna Stiekema, Koen K Van de Vijver, Henk Boot, Annegien Broeks, Catharina M Korse, Willemien J van Driel, Gemma G Kenter, Christianne A R Lok
BACKGROUND: An accurate diagnosis of cancer of Müllerian origin is required before the initiation of treatment. An overlap in clinical presentation and cytological, histological, or imaging studies with other nongynecological tumors does occur. Therefore, immunocytochemistry markers are used to determine tumor origin. Human epididymis protein 4 (HE4) is overexpressed in tissue of epithelial ovarian cancer (EOC). It has shown to be a sensitive and specific serum marker for EOC and to be of value for the differentiation between EOC and ovarian metastases of gastrointestinal origin...
March 2017: Cancer
https://www.readbyqxmd.com/read/28183788/prognostic-factors-in-ectopic-cushing-s-syndrome-due-to-neuroendocrine-tumors-a-multicenter-study
#15
MULTICENTER STUDY
Maria Vittoria Davi', Elisa Cosaro, Serena Piacentini, Giuseppe Reimondo, Nora Albiger, Giorgio Arnaldi, Antongiulio Faggiano, Giovanna Mantovani, Nicola Fazio, Alessandro Piovesan, Emanuela Arvat, Franco Grimaldi, Letizia Canu, Massimo Mannelli, Alberto Giacinto Ambrogio, Francesca Pecori Giraldi, Chiara Martini, Andrea Lania, Manuela Albertelli, Diego Ferone, Maria Chiara Zatelli, Davide Campana, Annamaria Colao, Carla Scaroni, Massimo Terzolo, Laura De Marinis, Sara Cingarlini, Rocco Micciolo, Giuseppe Francia
OBJECTIVE: Evidence is limited regarding outcome of patients with ectopic Cushing's syndrome (ECS) due to neuroendocrine tumors (NETs). DESIGN: We assessed the prognostic factors affecting the survival of patients with NETs and ECS. METHODS: Retrospective analysis of clinicopathological features, severity of hormonal syndrome, treatments from a large cohort of patients with NETs and ECS collected from 17 Italian centers. RESULTS: Our series included 110 patients, 58...
April 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28174381/-effectiveness-of-nivolumab-in-large-cell-neuroendocrine-carcinoma-of-the-lung-a-report-of-two-cases
#16
REVIEW
Wakako Daido, Masahiro Yamasaki, Naomi Saito, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Haruko Daga, Nobuyuki Ohashi
BACKGROUND: The anti-programmed death-1 antibody nivolumab is an important treatment option for non-small-cell lung carcinoma.However, its effectiveness for large-cell neuroendocrine carcinomas(LCNEC)is still controversial.Here, we report 2 cases of LCNECs that responded to nivolumab.Case 1: A 62-year-old man received chemotherapy and radiotherapy for stage III A lung adenocarcinoma.One year later, another lung lesion was observed and diagnosed as LCNEC using surgical lung biopsy.Although he subsequently received some chemotherapy regimens, the patient developed new brain metastasis, expanded mediastinal lesion, and increased levels of the tumor marker pro-gastrin releasing peptide(ProGRP)...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28168398/olfactory-neuroblastoma-with-divergent-differentiation-an-unusual-histologic-finding-in-a-rare-tumor
#17
Charles Meyer, Erin R S Hamersley, Rodolfo E Manosalva, Kevin Torske, Nicole McIntyre, Allen Mitchell
Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the sinonasal tract that arises from olfactory epithelium. There have been reports, mainly in tumors treated with chemoradiation or with distant metastases, describing focal histologic changes of divergent cell populations within archetypal ONB. Only three cases have been reported of ONB coexisting with non-neuroendocrine tumors. We describe our experience with a 35-year-old male with a nasal cavity mass extending into the anterior cranial fossa...
February 6, 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28153957/localization-of-unknown-primary-site-with-68ga-dotatoc-pet-ct-in-patients-with-metastatic-neuroendocrine-tumor
#18
Yusuf Menda, Thomas M O'Dorisio, James Howe, Michael King Schultz, Joseph Dillon, David Dick, Leonard G Watkins, Timothy Ginader, David L Bushnell, John Sunderland, Gideon Kd Zamba, Michael M Graham, M Sue O'Dorisio
Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. METHODS: A single-center prospective study was performed to evaluate the safety and efficacy of (68)Ga-DOTATOC PET/CT in patients with diagnosis of or suspected NET. A subgroup of patients with metastases and unknown primary after initial work-up was analyzed. The ((68)Ga)Ga-DOTATOC PET/CT was considered true positive if the positive primary site was confirmed by histology or follow-up imaging...
February 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28138732/limited-value-of-ga-68-dotatoc-pet-ct-in-routine-screening-of-patients-with-multiple-endocrine-neoplasia-type-1
#19
Max B Albers, Damiano Librizzi, Caroline L Lopez, Jerena Manoharan, Jonas C Apitzsch, Emily P Slater, Carmen Bollmann, Peter H Kann, Detlef K Bartsch
BACKGROUND: Routine screening is recommended for patients with multiple endocrine neoplasia type 1 (MEN1) to enable early detection and treatment of associated neuroendocrine neoplasms (NEN). Gallium(68)-DOTATOC-Positron emission tomography combined with computed tomography (Ga-68-DOTATOC-PET-CT) is a very sensitive and specific imaging technique for the detection of sporadic neuroendocrine tumors. The present study evaluated the value of Ga-68-DOTATOC-PET-CT in routine screening of patients with MEN1...
January 30, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28133140/-multiple-metachronal-liver-metastases-from-a-rectal-neuroendocrine-tumor-controlled-by-repeated-transcatheter-arterial-chemoembolization
#20
Yoshihiro Morimoto, Yoshinori Kagawa, Atsushi Naito, Takeshi Kato, Yasuo Oneda, Tomo Ishida, Yasufumi Sato, Ryuichi Kuwahara, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Atsushi Takeno, Yutaka Takeda, Shigeyuki Tamura
A 60-year-old woman was diagnosed with a rectal neuroendocrine tumor(NET)with SM invasion.We performed laparoscopic low anterior resection with D3 lymph node dissection.Pathological findings were rectal NET, G1, pSM(9,000 mm), ly0, v0, pN0, PM0, DM0, pR0, pStage I .Four years and 6 months later, contrast enhanced abdominal computed tomography (CECT)and contrast enhanced magnetic resonance imaging revealed multiple liver metastases.The tumors were unresectable because they were bilobar; therefore, we performed transcatheter arterial chemoembolizaion(TACE)...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
78252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"